Crossmark

Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm

Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s13023-017-0726-x

Published Online: 2018-01-17

Published Print: 2018-12

Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy

Authors

Sekijima, Yoshiki

Ueda, Mitsuharu

Koike, Haruki

Misawa, Sonoko

Ishii, Tomonori

Ando, Yukio
Funding

Funding for this research was provided by:

Pfizer Japan
License Information

Text and Data Mining valid from 2018-01-17
More Information

Article History

Received: 31 July 2017

Accepted: 23 November 2017

First Online: 17 January 2018

Change Date: 21 May 2019

Change Type: Correction

Change Details: .

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: YS, MU, HK, SM, and YA declare receipt of consulting fee or honorarium, support for travel to meetings, and provision for writing assistance from Pfizer Japan Inc. TI is employed by and has stock ownership in Pfizer Japan Inc.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.